Cancer Published date April 18, 2024 Abstract "Ovarian cancer ranks as a leading cause of mortality UCA1 expression inversely correlates with survival outcomes and therapy response in ovarian cancer clinical cancer xenografts, demonstrating the therapeutic potential of targeting LPAR-UCA1-let-7 axis in ovarian cancer. Carcinoma , Let-7 miRNAs , Oncogenic Pathways , Ovarian Cancer , Therapy Resistance , UCA1 , lncRNA

FTs, the origin of ovarian cancer, are known to express genes of serous tubal intraepithelial carcinoma PAR2 expression in FTs may serve as an early prediction sensor for ovarian cancer. We show now that knocking down Par2 inhibits ovarian cancer peritoneal dissemination in vivo, pointing The potent inhibitory function of Pc(4-4) is demonstrated via inhibition of ovarian cancer peritoneal serve as a powerful medicament in STICs and ovarian cancer.

cancer nanomedicines: from RNA sequencing data analysis to in vitro validation Published date July 27 , 2024 Abstract "Genetic heterogeneity in ovarian cancer indicates the need for personalised treatment To address the genetic heterogeneity of ovarian cancer, a future personalised approach could include cancer tissues. Subsequently, primary ovarian cancer cells derived from ascites and ovarian cancer cell lines were used

cancer cells by targeting PAR-1 Published date June 21, 2024 Abstract "We have purified Peptidase M84 cancer cells. PAR-1, a GPCR which is reported to be overexpressed in ovarian cancer cells, was identified as a target This evoked apoptotic death of the ovarian cancer cells through the intrinsic route. cancer."

Cancer Date & Time Friday, November 3rd / 3:55 PM Abstract Coming Soon About Robert Rottapel "Dr. for Cancer Research. He has focussed on developing a comprehensive map of ovarian cancer essential genes using whole genome to buffer cancer associated stress states. pancreatic cancer.

< GPCR News < GPCRs in Oncology and Immunology NPFF stimulates human ovarian cancer cell invasion by Epithelial ovarian cancer (EOC) is a leading cause of death among gynecological malignancies. Lanlan Fang , Peter C K Leung , Jung-Chien Cheng Tags Invasion , MMP-9 , NPFFR2 , Neuropeptide FF , Ovarian cancer Source Contribute to the GPCR News Coming soon Become a Contributor Classified GPCR News Call

coupled receptor-related gene signature through bioinformatics analysis to construct a risk model for ovarian cancer prognosis Published date June 18, 2024 Abstract " Background: Ovarian cancer (OV) is a common Method: We downloaded data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases Yongmei Li, Chunfang Ha Tags G protein-coupled receptor , Immune infiltration , Molecular marker , Ovarian cancer , Prognostic model , epithelial Source Contribute to the GPCR News Coming soon Become a Contributor

Oncology and Immunology PAXIP1-AS1 is associated with immune infiltration and predicts poor prognosis in ovarian cancer Published date August 15, 2023 Abstract "The long non-coding RNA (LncRNA) PAXIP1 antisense RNA 1 (PAXIP1-AS1) was found to promote proliferation, migration, EMT, and apoptosis of ovarian cancer ( infiltration of OC patients and its regulatory network are unclear. 379 OC tissues were collected from The Cancer Genome Atlas (TCGA) database. 427 OC tissues and 88 normal ovarian tissues were collected from GTEx

Minireview: functional roles of tissue kallikrein, kinins, and kallikrein-related peptidases in lung cancer Published date July 3, 2023 Abstract "Despite campaigns and improvements in detection and treatment, lung cancer One approach to treating patients suffering from lung cancer is to target surface receptors overexpressed , such as prostate and ovarian cancer, facilitating the invasive and metastatic capacity of tumor cells Since lung cancer is often diagnosed in advanced stages, our efforts should focus on early diagnosis,

< GPCR News < GPCRs in Oncology and Immunology Ovarian cancer G protein-coupled receptor 1 (OGR1) deficiency

The GHRHR has recently been highlighted as a promising drug target toward several types of cancer and has been shown to be overexpressed in prostate, breast, pancreatic, and ovarian cancer. Indeed, peptide GHRHR antagonists have displayed promising results in many cancer models.

November 3rd / 3:00 PM Coffee Break 4 Read More Friday, November 3rd / 3:30 PM G Proteins and GPCRs in Cancer November 3rd / 3:55 PM Inhibition of Relaxin Autocrine Signaling Confers Therapeutic Vulnerability in Ovarian Cancer Robert Rottapel University of Toronto Read More Friday, November 3rd / 4:20 PM Developing a PROTAC

Oncology and Immunology Expression prevalence and dynamics of GPCR somatostatin receptors 2 and 3 as cancer of receptors expression dynamics was performed for tumor-nodes-metastases (TNM) defined subgroups (ovarian

< GPCR News < GPCRs in Oncology and Immunology Chemokine Physiology in Cancer Published date November In cancer, chemokines play paradoxical roles in both the directed emigration of metastatic, receptor-expressing cancer cells out of the tumor as well as immigration of tumor infiltrating immune cells that culminate Facets of chemokine physiology across discrete cancer immune phenotypes are contrasted to existing chemokine-centered therapies in cancer.

< GPCR News < GPCRs in Oncology and Immunology Biochemical pharmacology of adenylyl cyclases in cancer date October 1, 2024 Abstract "Globally, despite extensive research and pharmacological advancement, cancer Understanding the signaling pathways involved in cancer progression is essential for the discovery of The expression patterns of ACs in numerous cancers are discussed. , G protein , GPCR , Hallmarks of Cancer , cAMP signaling .

< GPCR News < GPCRs in Oncology and Immunology GPR176 Promotes Cancer Progression by Interacting with G Protein GNAS to Restrain Cell Mitophagy in Colorectal Cancer Published date March 11, 2023 Abstract belongs to the G protein-coupled receptor superfamily, which responds to external stimuli and regulates cancer progression, but its role in colorectal cancer (CRC) remains unclear. In the present study, expression analyses of GPR176 are performed in patients with colorectal cancer.

< GPCR News < GPCRs in Oncology and Immunology The landscape of cancer-rewired GPCR signaling axes Published 2024 Abstract "We explored the dysregulation of G-protein-coupled receptor (GPCR) ligand systems in cancer Multiple GPCRs are differentially regulated together with their upstream partners across cancer subtypes Remarkably, we identified many such axes across several cancer molecular subtypes, including many involving , cancer cell lines , cell-cell communication , drug repurposing , personalized medicine , signaling

< GPCR News < GPCRs in Oncology and Immunology Role and recent progress of P2Y12 receptor in cancer development P2Y12R activation can promote platelet aggregation and adhesion to cancer cells, promote tumor angiogenesis immune microenvironment (TIME) and tumor drug resistance, which is conducive to the progression of cancers cancer. However, a new study suggests that long-term use of P2Y12R inhibitors may increase the risk of cancer

Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule G Proteins and GPCRs in Cancer Department of Pharmacology, School of Medicine, and Associate Director for Basic Science at the Moores Cancer treatments, and to identify novel multimodal strategies to enhance the response to cancer immunotherapies Silvio Gutkind on the web Gutkind Lab – UC San Diego Moores Cancer Center Gutkind Lab publications Pubmed LinkedIn Twitter UCSD Moores Cancer Center Dr.

GPCR News < GPCRs in Oncology and Immunology From odor to oncology: non-canonical odorant receptors in cancer sensory perception, emerging evidence suggests a compelling interplay between odorant receptors and cancer types, suggesting their contributions to cancer progression. The roles of these non-canonical chemoreceptors in cancer are complex, with some receptors promoting tumorigenesis and others acting as tumor-suppressing factors upon activation, depending on the cancer

News < GPCRs in Oncology and Immunology Agonists of galanin subtype 2 receptor may prevent pancreatic cancer and agonists of angiotensin II type 2 receptor may prevent colorectal cancer Published date June 24, of colorectal carcinoma (CRC) is better than that of PDAC, it still is the second-leading cause of cancer receptor inhibited the growth of GAL2 receptor-expressing patient-derived xenografts (PDX) of pancreatic cancer lanthionine-constrained agonist of angiotensin II type 2 (AT2) receptor inhibited PDX of colorectal cancer

< GPCRs in Oncology and Immunology GPR143 controls ESCRT-dependent exosome biogenesis and promotes cancer GPR143 is elevated in multiple cancers, and quantitative proteomic and RNA profiling of exosomes in human cancer cell lines showed that the GPR143-ESCRT pathway promotes secretion of exosomes that carry unique findings provide a mechanism for regulating the exosomal proteome and demonstrate its ability to promote cancer , Sun-Young Kong , Taejoon Kwon , Pann-Ghill Suh , Young Chan Chae Tags GPR143 , HRS , MVB , breast cancer

GPCRs in Oncology and Immunology Autocrine proteinase-activated receptor signaling in PC3 prostate cancer PARs are highly expressed in many cancer cells, including prostate cancer (PCa), and regulate various In this study, we examined the androgen-independent human prostatic cancer cell line PC3 and find the

GPCRs in Oncology and Immunology The β2-adrenergic receptor associates with CXCR4 multimers in human cancer found that CXCR4 assembles into multimeric complexes larger than dimers in MDA-MB-231 human breast cancer cells and in HCC4006 human lung cancer cells. These results suggest that CXCR4-β2AR heteromers are present in human cancer cells and that GPCR multimerization

in Oncology and Immunology Metabolic crosstalk: Extracellular ATP and the tumor microenvironment in cancer their respective di and mono-phosphate nucleoside forms, contributing significantly to immune biology, cancer

GPCR News < GPCRs in Oncology and Immunology Purinergic GPCR-integrin interactions drive pancreatic cancer P2RY2 presents as the purinergic gene with the strongest association with hypoxia, the highest cancer Moreover, receptor-integrin interactions were required for effective downstream signalling, leading to cancer This work elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential Ariana Samadi , Hemant M Kocher , Sabrina Simoncelli , Peter J McCormick , Richard Philip Grose Tags cancer

< GPCR News < GPCRs in Oncology and Immunology Ultrasensitive dose-response for asbestos cancer risk is expected for damage that accumulates in proportion to dose, as hypothesized for increased risk of cancer relation to genotoxic dose according to the multistage somatic mutation/clonal-expansion theory of cancer Mesothelioma and lung cancer induced by exposure to carcinogenic (e.g., certain asbestos) fibers in humans A recent Inflammation Somatic Mutation (ISM) theory of cancer posits instead that tissue-damage-associated

< GPCR News < GPCRs in Oncology and Immunology Pan-cancer functional analysis of somatic mutations in GPCRs) are the most frequently exploited drug target family, moreover they are often found mutated in cancer We explored cancer-related mutation patterns in all GPCR classes combined and individually. A Two-Entropy Analysis confirmed the correlation between residue conservation and cancer-related mutation families, but also discovered novel GPCRs which had not been linked to cancer before such as the P2Y